These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38779110)

  • 1. Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.
    Yoon CH; Groff C; Criss O
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
    Chowdhury S; Chowdhury NS
    Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
    Honig LS; Barakos J; Dhadda S; Kanekiyo M; Reyderman L; Irizarry M; Kramer LD; Swanson CJ; Sabbagh M
    Alzheimers Dement (N Y); 2023; 9(1):e12377. PubMed ID: 36949897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
    Qiao Y; Gu J; Yu M; Chi Y; Ma Y
    CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Aruffo E; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):863-881. PubMed ID: 37009976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.
    Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD
    J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease.
    Park J; Simpson C; Patel K
    Ann Pharmacother; 2024 Oct; 58(10):1045-1053. PubMed ID: 38095619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab.
    Gibson AW; Elser H; Rosso M; Cornblath EJ; Fonkeu Y; Prasad S; Rothstein A; Nasrallah IM; Wolk DA; Guo MH
    Alzheimers Dement; 2024 Nov; 20(11):8192-8197. PubMed ID: 39215494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
    Qiao Y; Chi Y; Zhang Q; Ma Y
    Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
    Vitek GE; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.
    Beshir SA; Hussain N; Menon VB; Al Haddad AHI; Al Zeer RAK; Elnour AA
    Int J Alzheimers Dis; 2024; 2024():2052142. PubMed ID: 39081336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
    Doran SJ; Sawyer RP
    Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.